ARNO THERAPEUTICS COM USD0.0001 (ARNI)

0.86
0.07 8.18
OTC
Prev Close 0.80
Open 0.80
Day Low/High 0.80 / 0.89
52 Wk Low/High 0.18 / 0.92
Volume 23.08K
Exchange OTC
Shares Outstanding 41.56B
Market Cap 21.61M
Div & Yield N.A. (N.A)

Latest News

Arno Therapeutics Completes $7.4 Million Common Stock Financing

Arno Therapeutics Completes $7.4 Million Common Stock Financing

Plus Appoints Jay Moorin to Board of Directors and Stuart Holden, MD as SAB Chair

Arno Therapeutics Data Demonstrate AR-12 As Novel Antifungal Drug Against Common Finger And Toenail Fungus, Onychomycosis

Arno Therapeutics Data Demonstrate AR-12 As Novel Antifungal Drug Against Common Finger And Toenail Fungus, Onychomycosis

Presentation Thursday, October 29 at AAPS Annual Meeting

Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

Data From Preclinical In Vitro Study Presented Today at 15th European AIDS Conference

Arno Therapeutics' AR-13 Data Show Promise As Potential New Therapeutic Option For Cystic Fibrosis Patients With Serious Bacterial Infections

Arno Therapeutics' AR-13 Data Show Promise As Potential New Therapeutic Option For Cystic Fibrosis Patients With Serious Bacterial Infections

Dataset Being Presented at Upcoming 29th Annual North American Cystic Fibrosis Conference

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity Of AR-12, Identified It As Lead Compound Of New Class Of Drugs

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity Of AR-12, Identified It As Lead Compound Of New Class Of Drugs

Podium Presentation and Data Posters Presented at ICAAC/ICC 2015 on Saturday, Sept. 19

Arno Therapeutics Receives Authorization To Proceed With Modified Phase I/II Trial Evaluating Onapristone In Prostate Cancer

Arno Therapeutics Receives Authorization To Proceed With Modified Phase I/II Trial Evaluating Onapristone In Prostate Cancer

Phase II to Include Study of Onapristone in Combination With Abiraterone

Arno Therapeutics Announces Issuance Of First Onapristone Patent

Arno Therapeutics Announces Issuance Of First Onapristone Patent

Patent Covers Methods and Systems for Identifying and Treating Patients With Anti-Progestin Susceptible Tumors

Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online In Antiviral Research

Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online In Antiviral Research

Data Demonstrate In-Vitro Activity Against Ebola and Other Hemorrhagic Fever Viruses

Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity For AR-12

Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity For AR-12

Data Presented at the 28th Annual International Conference on Antiviral Research (ICAR)

Arno Therapeutics Announces Data Validating Continued Onapristone And Companion Diagnostic Development At ASCO Annual Meeting 2015

Arno Therapeutics Announces Data Validating Continued Onapristone And Companion Diagnostic Development At ASCO Annual Meeting 2015

Data From Three Abstracts to be Presented Saturday, May 30 During 'Gynecologic Cancer' and 'Genitourinary (Prostate) Cancer' Poster Sessions

Arno Therapeutics To Present Promising Data From Phase I Trial Of Onapristone At AACR Annual Meeting 2015

Arno Therapeutics To Present Promising Data From Phase I Trial Of Onapristone At AACR Annual Meeting 2015

Three Posters Support the Ongoing Clinical Development Program of Lead Compound

New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published In The Journal Of Urology

New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published In The Journal Of Urology

Demonstrate Synergetic Anti-Tumor Effects of AR-42 With Cisplatin in Bladder Cancer Models